TUCSON, Ariz.--(BUSINESS WIRE)--ImaRx Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to its proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in this offering will be offered by ImaRx Therapeutics.
Maxim Group, LLC is acting as underwriter and book-running manager for the proposed offering.
The offering will only be made by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from Maxim Group Syndicate Department: 405 Lexington Ave., New York, NY, 10174; by telephone 212-895-3575, Fax 212-895-3828 or email request at email@example.com.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.
About ImaRx Therapeutics
ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. ImaRx Therapeutics' commercialization efforts are currently focused on its product, Abbokinase®, for the treatment of acute massive pulmonary embolism.
ImaRx Therapeutics, Inc.
Greg Cobb, Chief Financial Officer, 520-770-1259
Lippert/Heilshorn & Associates
Bruce Voss or Don Markley, 310-691-7100
Source: ImaRx Therapeutics, Inc.
>>> Discuss This Story